Combination immunotherapy with 4-1BBL and CTLA-4 blockade for the treatment of prostate cancer

Clinical and Developmental Immunology

Volumn 2012, Issue , 2012, Pages

  Kuang, Youlin ^a   Zhang, Li ^a   Weng, Xiaodong ^a   Liu, Xiuheng ^a   Zhu, Hengchen ^a  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CD137 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; GAMMA INTERFERON; INTERLEUKIN 2; MONOCLONAL ANTIBODY 9H10; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNOTHERAPY; CELL SURVIVAL; CONTROLLED STUDY; CYTOKINE RELEASE; FEMALE; IMMUNOREGULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR CELL; TUMOR REGRESSION;

EID: 84863234723     PISSN: 17402522     EISSN: 17402530     Source Type: Journal    
DOI: 10.1155/2012/439235     Document Type: Article

References (29)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., Thun M. J., Cancer statistics, 2008 CA Cancer Journal for Clinicians 2008 58 2 71 96 (Pubitemid 351521864)
2. Aldrich J. F., Lowe D. B., Shearer M. H., Winn R. E., Jumper C. A., Kennedy R. C., Vaccines and immunotherapeutics for the treatment of malignant disease Clinical and Developmental Immunology 2010 2010
3. Guinn B. A., Bertram E. M., DeBenedette M. A., Berinstein N. L., Watts T. H., 4-1BBL enhances anti-tumor responses in the presence or absence of CD28 but CD28 is required for protective immunity against parental tumors Cellular Immunology 2001 210 1 56 65 (Pubitemid 32756942)
4. Habib-Agahi M., Phan T. T., Searle P. F., Co-stimulation with 4-1BB ligand allows extended T-cell proliferation, synergizes with CD80/CD86 and can reactivate anergic T cells International Immunology 2007 19 12 1383 1394 (Pubitemid 350131344)
5. Breckpot K., Escors D., Dendritic cells for active anti-cancer immunotherapy: targeting activation pathways through genetic modification Endocrine, Metabolic and Immune DisordersDrug Targets 2009 9 4 328 343
6. Li Q., Ai J., Song Z., Liu J., Shan B., 4-1BB (CD137) ligand enhanced anti-tumor immune response against mouse forestomach carcinoma in vivo Cellular Molecular Immunology 2008 5 5 379 384
7. Yan X., Johnson B. D., Orentas R. J., Induction of a VLA-2 (CD49b)-expressing effector T cell population by a cell-based neuroblastoma vaccine expressing CD137L Journal of Immunology 2008 181 7 4621 4631
8. Wilcox R. A., Tamada K., Strome S. E., Chen L., Signaling through NK cell-associated CD137 promotes both helper function for CD8 + cytolytic T cells and responsiveness to IL-2 but not cytolytic activity Journal of Immunology 2002 169 8 4230 4236 (Pubitemid 35178194)
9. Cannons J. L., Lau P., Ghumman B., DeBenedette M. A., Yagita H., Okumura K., Watts T. H., 4-1BB ligand induces cell division, sustains survival, and enhances effector function of CD4 and CD8 T cells with similar efficacy Journal of Immunology 2001 167 3 1313 1324 (Pubitemid 32703127)
10. Wilcox R. A., Tamada K., Flies D. B., Zhu G., Chapoval A. I., Blazar B. R., Kast W. M., Chen L., Ligation of CD137 receptor prevents and reverses established anergy of CD8 + cytolytic T lymphocytes in vivo Blood 2004 103 1 177 184 (Pubitemid 38029936)
11. Habib-Agahi M., Jaberipour M., Searle P. F., 4-1BBL costimulation retrieves CD28 expression in activated T cells Cellular Immunology 2009 256 1-2 39 46
12. Sharma R. K., Elpek K. G., Yolcu E. S., Schabowsky R. H., Zhao H., Bandura-Morgan L., Shirwan H., Costimulation as a platform for the development of vaccines: a peptide-based vaccine containing a novel form of 4-1BB ligand eradicates established tumors Cancer Research 2009 69 10 4319 4326
13. Hodi F. S., Cytotoxic T-lymphocyte-associated antigen-4 Clinical Cancer Research 2007 13 18 5238 5242 (Pubitemid 47510345)
14. van Elsas A., Hurwitz A. A., Allison J. P., Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony- stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation Journal of Experimental Medicine 1999 190 3 355 366 (Pubitemid 29374833)
15. Met O., Wang M., Pedersen A. E., Nissen M. H., Buus S., Claesson M. H., The effect of a therapeutic dendritic cell-based cancer vaccination depends on the blockage of CTLA-4 signaling Cancer Letters 2006 231 2 247 256 (Pubitemid 43038735)
16. Sotomayor E. M., Borrello I., Tubb E., Allison J. P., Levitsky H. I., In vivo blockade of CTLA-4 enhances the priming of responsive T cells but fails to prevent the induction of tumor antigen-specific tolerance Proceedings of the National Academy of Sciences of the United States of America 1999 96 20 11476 11481 (Pubitemid 29487405)
17. Zhang F., Huang G., Hu B., Song Y., Shi Y., Induction of immune tolerance in asthmatic mice by vaccination with DNA encoding an allergen-cytotoxic T lymphocyte-associated antigen 4 combination Clinical and Vaccine Immunology 2011 18 5 807 814
18. Elkord E., Immunology and immunotherapy approaches for prostate cancer Prostate Cancer and Prostatic Diseases 2007 10 3 224 236 (Pubitemid 47351401)
19. Lu Z. Y., Condomines M., Tarte K., Nadal L., Delteil M. C., Rossi J. F., Ferrand C., Klein B., B7-1 and 4-1BB ligand expression on a myeloma cell line makes it possible to expand autologous tumor-specific cytotoxic T cells in vitro Experimental Hematology 2007 35 3 443 453
20. Laderach D., Movassagh M., Johnson A., Mittler R. S., Galy A., 4-1BB co-stimulation enhances human CD8 + T cell priming by augmenting the proliferation and survival of effector CD8 + T cells International Immunology 2002 14 10 1155 1167 (Pubitemid 35175223)
21. Lee H. W., Park S. J., Choi B. K., Kim H. H., Nam K. O., Kwon B. S., 4-1BB promotes the survival of CD8 + T lymphocytes by increasing expression of Bcl-xL and Bfl-1 Journal of Immunology 2002 169 9 4882 4888 (Pubitemid 35217152)
22. Croft M., Co-stimulatory members of the TNFR family: keys to effective T-cell immunity? Nature Reviews Immunology 2003 3 8 609 620 (Pubitemid 37328664)
23. Kudo-Saito C., Hodge J. W., Kwak H., Kim-Schulze S., Schlom J., Kaufman H. L., 4-1BB ligand enhances tumor-specific immunity of poxvirus vaccines Vaccine 2006 24 23 4975 4986 (Pubitemid 43782689)
24. Xiao H., Huang B., Yuan Y., Li D., Han L. F., Liu Y., Gong W., Wu F. H., Zhang G. M., Feng Z. H., Soluble PD-1 facilitates 4-1BBLTriggered antitumor immunity against murine H22 hepatocarcinoma in vivo Clinical Cancer Research 2007 13 6 1823 1830 (Pubitemid 46952952)
25. Li Q., Iuchi T., Jure-Kunkel M. N., Chang A. E., Adjuvant effect of anti-4-1BB mAb administration in adoptive T cell therapy of cancer International Journal of Biological Sciences 2007 3 7 455 462 (Pubitemid 350277606)
26. Lynch D. H., The promise of 4-1BB (CD137)-mediated immunomodulation and the immunotherapy of cancer Immunological Reviews 2008 222 1 277 286 (Pubitemid 351430383)
27. Wang C., Lin G. H. Y., McPherson A. J., Watts T. H., Immune regulation by 4-1BB and 4-1BBL: complexities and challenges Immunological Reviews 2009 229 1 192 215
28. Kocak E., Lute K., Chang X., May K. F., Exten K. R., Zhang H., Abdessalam S. F., Lehman A. M., Jarjoura D., Zheng P., Liu Y., Combination therapy with anti-CTL antigen-4 and anti-4-1BB antibodies enhances cancer immunity and reduces autoimmunity Cancer Research 2006 66 14 7276 7284 (Pubitemid 44197709)
29. Curran M. A., Kim M., Montalvo W., Al-Shamkhani A., Allison J. P., Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production PLoS ONE 2011 6 4